<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Patient Prefer Adherence</journal-id><journal-id journal-id-type="iso-abbrev">Patient Prefer Adherence</journal-id><journal-title-group><journal-title>Patient preference and adherence</journal-title></journal-title-group><issn pub-type="epub">1177-889X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23077409</article-id><article-id pub-id-type="pmc">3474173</article-id><article-id pub-id-type="doi">10.2147/PPA.S36320</article-id><article-id pub-id-type="publisher-id">ppa-6-725</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Evaluation of a prototype electronic personal health record for patients with idiopathic thrombocytopenic purpura</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chiche</surname><given-names>Laurent</given-names></name><xref ref-type="aff" rid="af1-ppa-6-725">1</xref><xref ref-type="corresp" rid="c1-ppa-6-725"></xref></contrib><contrib contrib-type="author"><name><surname>Brescianini</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="af1-ppa-6-725">1</xref></contrib><contrib contrib-type="author"><name><surname>Mancini</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="af2-ppa-6-725">2</xref></contrib><contrib contrib-type="author"><name><surname>Servy</surname><given-names>Hervé</given-names></name><xref ref-type="aff" rid="af3-ppa-6-725">3</xref></contrib><contrib contrib-type="author"><name><surname>Durand</surname><given-names>Jean-Marc</given-names></name><xref ref-type="aff" rid="af1-ppa-6-725">1</xref></contrib></contrib-group><aff id="af1-ppa-6-725"><label>1</label>Service de Médecine Interne, Centre de Compétence pour la prise en charge des Cytopénies Auto-immunes, Hôpital de la Conception, Marseille</aff><aff id="af2-ppa-6-725"><label>2</label>Service de Santé Publique, Hôpital de la Timone, Marseille</aff><aff id="af3-ppa-6-725"><label>3</label>Association AIMSU, Maison des Associations, La Ciotat, France</aff><author-notes><corresp id="c1-ppa-6-725">Correspondence: Laurent Chiche, Service de Médecine Interne, CHU Conception, 147 Boulevard Baille, 13005 Marseille, France, Tel +33 49138 3762, Fax +33 49 138 3768, Email <email>laurent.chiche@ap-hm.fr</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2012</year></pub-date><volume>6</volume><fpage>725</fpage><lpage>734</lpage><permissions><copyright-statement>© 2012 Chiche et al, publisher and licensee Dove Medical Press Ltd.</copyright-statement><copyright-year>2012</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="3201" xml_f="3211" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3222" xml_f="3865" txt_i="22" txt_f="665">Patients with rare diseases often lack information about the disease itself and appropriate health care, leading to poor quality of life. Personal health records provide health information which can then be shared between multiple health care providers. Personal health records may also offer a tool for capturing patients’ reported outcomes, thus enhancing their empowerment and improving communication with health care professionals. We conducted a pilot study to evaluate the usability of Sanoia, a freely accessible personal health record, which was customized for patients with the rare disease, idiopathic thrombocytopenic purpura (ITP).</offsets></p></sec><sec><title><offsets xml_i="3887" xml_f="3894" txt_i="667" txt_f="674">Methods</offsets></title><p><offsets xml_i="3905" xml_f="4465" txt_i="675" txt_f="1235">The Sanoia interface was expanded with ITP-specific tools. A prospective study was conducted at the referent center to evaluate the usability of this new interface (referred to here as the “tool”) by patients. Forty-three patients were randomized into groups to use or to not use the tool. Its use was evaluated by a specific questionnaire and by surveying individual patient adherence profiles. Evaluation of health-related quality of life using the ITP patient assessment questionnaire, was performed at baseline and after 1, 3, and 6 months via postal mail.</offsets></p></sec><sec><title><offsets xml_i="4487" xml_f="4494" txt_i="1237" txt_f="1244">Results</offsets></title><p><offsets xml_i="4505" xml_f="5024" txt_i="1245" txt_f="1764">The groups were similar at inclusion in terms of characteristics, including global quality of life. During the study period, the tool was used to update the personal records of 19/28 patients (68%), with a median of two connections to the tool (range 1–12) plus access by various health care professionals (n = 22). In addition, 15/19 (78%) patients used the “personal notes” section at least once. We observed no significant changes in quality of life between patients with or without the tool during the study period.</offsets></p></sec><sec><title><offsets xml_i="5046" xml_f="5056" txt_i="1766" txt_f="1776">Conclusion</offsets></title><p><offsets xml_i="5067" xml_f="5310" txt_i="1777" txt_f="2020">This pilot study demonstrates the good usability of the new customized Sanoia interface for patients with ITP. Additional studies will increase its usability further, and its interface could be adapted for use with other rare chronic diseases.</offsets></p></sec></abstract><kwd-group><kwd>electronic personal health records</kwd><kwd>rare diseases</kwd><kwd>idiopathic thrombocytopenic purpura</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="5510" xml_f="5522" txt_i="2029" txt_f="2041">Introduction</offsets></title><p><offsets xml_i="5533" xml_f="5638" txt_i="2042" txt_f="2144">Worldwide, there are an estimated 7000 different rare chronic diseases (ie, affecting &lt;1/2000 people).</offsets><xref ref-type="bibr" rid="b1-ppa-6-725"><offsets xml_i="5679" xml_f="5680" txt_i="2144" txt_f="2145">1</offsets></xref><offsets xml_i="5687" xml_f="5934" txt_i="2145" txt_f="2392"> In addition to their frequent severity and/or absence of validated treatments, patients with rare diseases often lack information about the disease itself and its appropriate care, which ideally should combine many different spheres of expertise.</offsets></p><p><offsets xml_i="5941" xml_f="6191" txt_i="2393" txt_f="2643">Adult immune thrombocytopenic purpura (ITP) is a rare chronic autoimmune disorder characterized by antibody-mediated platelet destruction, often leading to bleeding symptoms that may range from mild bruising and mucosal bleeding to severe hemorrhage.</offsets><xref ref-type="bibr" rid="b2-ppa-6-725"><offsets xml_i="6232" xml_f="6233" txt_i="2643" txt_f="2644">2</offsets></xref><offsets xml_i="6240" xml_f="6328" txt_i="2644" txt_f="2732"> Patients also often complain of fatigue and report poor health-related quality of life.</offsets><xref ref-type="bibr" rid="b3-ppa-6-725"><offsets xml_i="6369" xml_f="6370" txt_i="2732" txt_f="2733">3</offsets></xref><offsets xml_i="6377" xml_f="6566" txt_i="2733" txt_f="2922"> The treatment-related side effects and quality of life for these patients, including limitations to occupation and daily activities, have only recently become a focus of clinical research.</offsets></p><p><offsets xml_i="6573" xml_f="7094" txt_i="2923" txt_f="3444">Personal health records and their potential application in rare diseases have rarely been evaluated. Yet, these can provide health information and allow information to be shared between multiple health care providers, which is particularly important when patients are away from their referent center. Also, personal health records offer tools for capturing patient-reported outcomes (eg, pain, symptoms, self-scoring), which may enhance patient empowerment as well as improve communication with health care professionals.</offsets></p><p><offsets xml_i="7101" xml_f="7283" txt_i="3445" txt_f="3624">In France, Sanoia has recently developed a freely accessible personal health record interface that fully addresses privacy concerns and is already being used by &gt;120,000 patients.</offsets><xref ref-type="bibr" rid="b4-ppa-6-725"><offsets xml_i="7324" xml_f="7325" txt_i="3624" txt_f="3625">4</offsets></xref><offsets xml_i="7332" xml_f="7505" txt_i="3625" txt_f="3798"> We designed a prototype specifically customized for patients with ITP and conducted a pilot 6-month study to evaluate its usability and potential impact on quality of life.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="7556" xml_f="7577" txt_i="3800" txt_f="3821">Materials and methods</offsets></title><sec><title><offsets xml_i="7597" xml_f="7617" txt_i="3822" txt_f="3842">Creation of the tool</offsets></title><p><offsets xml_i="7628" xml_f="7938" txt_i="3843" txt_f="4153">This study was conducted at the referent center, the Hospital Conception (Centre de Compétence, Marseille, France), which diagnoses and manages ITP. Sanoia has developed a web tool integrated with electronic personal health records, which offers full privacy protection using an innovative anonymity technique.</offsets><xref ref-type="bibr" rid="b4-ppa-6-725"><offsets xml_i="7979" xml_f="7980" txt_i="4153" txt_f="4154">4</offsets></xref><offsets xml_i="7987" xml_f="8137" txt_i="4154" txt_f="4304"> The tool already includes numerous factors related to chronic disease, ie, vaccination records, allergies, prescription history, previous symptoms ( </offsets><xref ref-type="fig" rid="f1-ppa-6-725"><offsets xml_i="8177" xml_f="8186" txt_i="4304" txt_f="4313">Figure 1A</offsets></xref><offsets xml_i="8193" xml_f="8222" txt_i="4313" txt_f="4342">), and medical test results (</offsets><xref ref-type="fig" rid="f1-ppa-6-725"><offsets xml_i="8262" xml_f="8271" txt_i="4342" txt_f="4351">Figure 1B</offsets></xref><offsets xml_i="8278" xml_f="8476" txt_i="4351" txt_f="4549">). Once the patient has created his/her personal health record, they receive a unique personal identifier online that they can keep with them and communicate to a physician or health care provider (</offsets><xref ref-type="fig" rid="f1-ppa-6-725"><offsets xml_i="8516" xml_f="8525" txt_i="4549" txt_f="4558">Figure 1C</offsets></xref><offsets xml_i="8532" xml_f="8615" txt_i="4558" txt_f="4641">). The latter can then access the patient’s medical information in four languages (</offsets><xref ref-type="fig" rid="f1-ppa-6-725"><offsets xml_i="8655" xml_f="8664" txt_i="4641" txt_f="4650">Figure 1D</offsets></xref><offsets xml_i="8671" xml_f="8798" txt_i="4650" txt_f="4777">). Notably, only the patient has the personal password needed to modify and update the content of their personal health record.</offsets></p><p><offsets xml_i="8805" xml_f="9020" txt_i="4778" txt_f="4993">In collaboration with physicians from the center, the existing interface of the Sanoia was expanded with ITP-specific tools, which included a link to ITP-related web resources that had been validated by physicians (</offsets><xref ref-type="fig" rid="f2-ppa-6-725"><offsets xml_i="9060" xml_f="9069" txt_i="4993" txt_f="5002">Figure 2A</offsets></xref><offsets xml_i="9076" xml_f="9160" txt_i="5002" txt_f="5086">), and an online emergency protocol, created from updated national recommendations. </offsets><xref ref-type="bibr" rid="b7-ppa-6-725"><offsets xml_i="9201" xml_f="9202" txt_i="5086" txt_f="5087">7</offsets></xref><offsets xml_i="9209" xml_f="9357" txt_i="5087" txt_f="5235"> The Sanoia interface has also been modified to allow patients to take personal (bloc) notes of symptoms, medications, and any intercurrent events (</offsets><xref ref-type="fig" rid="f2-ppa-6-725"><offsets xml_i="9397" xml_f="9406" txt_i="5235" txt_f="5244">Figure 2B</offsets></xref><offsets xml_i="9413" xml_f="9473" txt_i="5244" txt_f="5304">). The new interface is hereafter referred to as the “tool”.</offsets></p></sec><sec><title><offsets xml_i="9495" xml_f="9515" txt_i="5306" txt_f="5326">Prototype evaluation</offsets></title><p><offsets xml_i="9526" xml_f="10217" txt_i="5327" txt_f="6018">The principal aim of this 6-month prospective study was to evaluate the usability of the tool by patients with ITP. The secondary aim was to evaluate its potential impact on quality of life. To avoid any bias caused by selection of patients who might be more confident with the use of computers, patients with ITP hospitalized at the center between 2000 and 2010 were randomly and directly contacted by telephone to participate in the study. For this pilot study, we planned to enroll between 10 and 15 patients per group (see below). Eligible patients were men or women aged between 18 and 75 years with a diagnosis of chronic ITP according to the American Society of Hematology guidelines,</offsets><xref ref-type="bibr" rid="b3-ppa-6-725"><offsets xml_i="10258" xml_f="10259" txt_i="6018" txt_f="6019">3</offsets></xref><offsets xml_i="10266" xml_f="10420" txt_i="6019" txt_f="6173"> permanent web access, and no neuropsychiatric conditions. After providing their written consent, the patients enrolled were randomized into three groups.</offsets></p><p><offsets xml_i="10427" xml_f="11217" txt_i="6174" txt_f="6964">Groups 2 and 3 had personal health records initiated at the center during their first visit. Basic instructions concerning the use of the study tool were provided by resource personnel, and all patients received a printed manual (see Supplementary data). Those assigned to group 3 were also able to contact resource personnel (by phone and/or email) throughout the study period. The usability of the tool was evaluated by a specific questionnaire (including use of the tool by the patient alone or with a health care professional) and, more objectively, by surveying the number of individual times the patients connected with the tool, either to update personal records or to use it with a health care professional. After 3 months, the usage profiles were determined as previously reported.</offsets><xref ref-type="bibr" rid="b5-ppa-6-725"><offsets xml_i="11258" xml_f="11259" txt_i="6964" txt_f="6965">5</offsets></xref></p><p><offsets xml_i="11273" xml_f="11599" txt_i="6966" txt_f="7289">Briefly, patients were classified as nonadherent, adherent, or very adherent if they connected on &lt;2, 2, or ≥3 occasions with the tool, respectively (not including access by professionals). Demographic and medical data, as well as evaluation of health-related quality of life, using the ITP patient assessment questionnaire</offsets><xref ref-type="bibr" rid="b4-ppa-6-725"><offsets xml_i="11640" xml_f="11641" txt_i="7289" txt_f="7290">4</offsets></xref><offsets xml_i="11648" xml_f="11882" txt_i="7290" txt_f="7524"> were recorded at inclusion and at 1, 3, and 6 months via postal mail (see questionnaire in the Supplementary data). Group 1 comprised controls and had no access to the tool, and these patients were only evaluated for quality of life.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="11929" xml_f="11936" txt_i="7527" txt_f="7534">Results</offsets></title><p><offsets xml_i="11947" xml_f="12302" txt_i="7535" txt_f="7890">Forty-three of 72 patients who were contacted (15 were not interested and 14 did not fulfill the inclusion criteria), were enrolled and randomized into three groups (n = 15, n = 14, and n = 14, respectively, in groups 1, 2, and 3). At inclusion, clinical and biological characteristics, as well as global quality of life, were similar between the groups (</offsets><xref ref-type="table" rid="t1-ppa-6-725"><offsets xml_i="12344" xml_f="12352" txt_i="7890" txt_f="7898">Tables 1</offsets></xref><offsets xml_i="12359" xml_f="12364" txt_i="7898" txt_f="7903"> and </offsets><xref ref-type="table" rid="t2-ppa-6-725"><offsets xml_i="12406" xml_f="12407" txt_i="7903" txt_f="7904">2</offsets></xref><offsets xml_i="12414" xml_f="12416" txt_i="7904" txt_f="7906">).</offsets></p><p><offsets xml_i="12423" xml_f="12508" txt_i="7907" txt_f="7992">Results concerning the usability of the tool during the study period are reported in </offsets><xref ref-type="table" rid="t2-ppa-6-725"><offsets xml_i="12550" xml_f="12557" txt_i="7992" txt_f="7999">Table 2</offsets></xref><offsets xml_i="12564" xml_f="13284" txt_i="7999" txt_f="8719">. Data reported by patients in the questionnaires were in complete agreement with the number of connections to the tool recorded during the study period. The tool was used to update personal records by 19/28 patients (68%), with each of the 19 patients making a median of two connections (range 1–12). In month 3, heterogeneous usage profiles were observed between patients from groups 2 and 3, which were classified as nonadherent (less than two connections), adherent (two connections), or very adherent (at least three connections) in 28%, 40%, and 32%, respectively. Except for being older, no other differences were observed between very adherent and nonadherent patients (mean age 57 versus 44 years respectively, </offsets><italic><offsets xml_i="13292" xml_f="13293" txt_i="8719" txt_f="8720">P</offsets></italic><offsets xml_i="13302" xml_f="13362" txt_i="8720" txt_f="8780"> = 0.04) with regards to their characteristics at inclusion.</offsets></p><p><offsets xml_i="13369" xml_f="13920" txt_i="8781" txt_f="9332">During the study period, patients used the tool with various health care professionals: general practitioners (n = 11), dentists (n = 2), nurses (n = 1), specialists (cardiologist, internist, or ophthalmologist, n = 5), or physiotherapists (n = 3). Notably, patients did not report any refusal from health care professionals to use information from the tool during a consultation. In addition, 15/19 (78%) used the personal notes section at least once for various reasons (to report symptoms or medical events, to write questions to ask their doctor).</offsets></p><p><offsets xml_i="13927" xml_f="14311" txt_i="9333" txt_f="9717">Of note, patients from group 3 had no contact with resource personnel, likely because they received adequate information through the instructions provided during initiation of the tool and in its dedicated manual. During the study period, we observed no significant changes in quality of life between patients from group 2 and 3, or in patients from group 1 who did not use the tool (</offsets><xref ref-type="table" rid="t2-ppa-6-725"><offsets xml_i="14353" xml_f="14360" txt_i="9717" txt_f="9724">Table 2</offsets></xref><offsets xml_i="14367" xml_f="14369" txt_i="9724" txt_f="9726">).</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="14413" xml_f="14423" txt_i="9728" txt_f="9738">Discussion</offsets></title><p><offsets xml_i="14434" xml_f="15032" txt_i="9739" txt_f="10337">The use of electronic personal health records has recently increased in spite of concerns regarding the privacy of recorded data. This first pilot study confirms the usability of a self-managed personal health record interface which was specifically customized for patients with a specific rare disease, ie, ITP. Indeed, 68% of patients used the tool effectively, and 72% of these met criteria for good and very good adherence. Also, the tool was not only used for updating the personal health record, but also during consultations with various health care professionals and to make personal notes.</offsets></p><p><offsets xml_i="15039" xml_f="15623" txt_i="10338" txt_f="10922">The usefulness of this tool relies on patients’ understanding and using their records appropriately. The help provided directly by the hospital during initiation of the tool, as well as the creation of a specific manual to guide first users, were probably key factors in enabling its good adoption. However, we observed varying levels of usage of the tool, so additional research is needed to identify possible barriers to adoption. Interestingly, a previous study has reported increased usability of a similar tool by patients with asthma who used mobile phones instead of computers.</offsets><xref ref-type="bibr" rid="b6-ppa-6-725"><offsets xml_i="15664" xml_f="15665" txt_i="10922" txt_f="10923">6</offsets></xref><offsets xml_i="15672" xml_f="15865" txt_i="10923" txt_f="11116"> Sanoia have recently implemented an interface for mobile phones. Thus, future studies involving the tool could also evaluate the impact of this parameter on the usability by patients with ITP.</offsets></p><p><offsets xml_i="15872" xml_f="16292" txt_i="11117" txt_f="11537">During the study period, we did not observe a significant impact on quality of life. This negative result may be linked to our small sample size, which precluded any statistical per protocol analyses (ie, studying the impact of quality of life only in those who could effectively use the tool). Alternatively, the impaired quality of life at inclusion of our patients was not as severe as that reported in other studies.</offsets><xref ref-type="bibr" rid="b7-ppa-6-725"><offsets xml_i="16333" xml_f="16334" txt_i="11537" txt_f="11538">7</offsets></xref><offsets xml_i="16341" xml_f="16624" txt_i="11538" txt_f="11821"> During the study period, none of the enrolled patients presented with a flare-up of their disease. Thus, the actual impact of the tool on patient health outcomes and well-being should be evaluated further in more patients, with other severe/active diseases, and for a longer period.</offsets></p><p><offsets xml_i="16631" xml_f="17062" txt_i="11822" txt_f="12253">In conclusion, we found that patients with ITP, a rare disease, adapted satisfactorily to using the electronic personal health record with the Sanoia interface. Even though this study did not show a significant improvement in health-related quality of life, it has demonstrated the usability of this customized and freely accessible Sanoia interface, which could potentially be adapted for use by patients with other rare diseases.</offsets></p></sec></body><back><ack><title>Acknowledgment</title><p>We thank all patients who participated in this study, as well as the physicians involved in designing the tool.</p></ack><fn-group><fn id="fn1-ppa-6-725"><p><bold>Disclosure</bold></p><p>Hervé Servy is the founder of Sanoia, and received a grant from Amgen to support this work. Other authors have no conflicts of interest to report.</p></fn></fn-group><app-group><app><title>Appendix</title><sec><title>Patient questionnaire</title><p>Surname:</p><p>Name:</p><p>ISAN:</p></sec><sec><title>Physical health</title><sec><title>Symptom scale</title><p>(10-point Likert scale from all the time to never)</p><p>In the past four weeks how often did you:</p><list list-type="bullet"><list-item><p>Have either bruising or petechiae (broken blood vessels)?</p></list-item><list-item><p>Have wounds or scars from blood tests, injections, or intravenous needles?</p></list-item><list-item><p>Have blood blisters in your mouth?</p></list-item><list-item><p>Have bleeding episodes (nose bleeds, gum bleeds)?</p></list-item><list-item><p>Have muscle aches?</p></list-item><list-item><p>Have cramps in your legs?</p></list-item></list></sec><sec><title>Fatigue/sleep scale</title><p>(10-point Likert scale from all the time to never)</p><p>In the past four weeks how often did ITP or its treatment:</p><list list-type="bullet"><list-item><p>Cause you to have difficulty falling asleep at bedtime?</p></list-item><list-item><p>Cause you to awaken during the night?</p></list-item><list-item><p>Cause you to feel sleepy during the daytime?</p></list-item><list-item><p>Cause you to feel physically fatigued?</p></list-item></list></sec><sec><title>Bother scale</title><p>In the past four weeks:</p><list list-type="simple"><list-item><p>11. How often did you feel physically unattractive due to bruising, scarring, wounds, or effects of ITP medications? (10-point Likert scale from all the time to never)</p></list-item><list-item><p>12. Overall, to what extent have ITP and its treatment affected your physical health? (10-point Likert scale from extremely to not at all)</p></list-item><list-item><p>13. Overall, how bothered have you been by the effect of ITP and its treatment on your physical health? (10-point Likert scale from extremely to not at all)</p></list-item></list></sec><sec><title>Activity scale</title><p>(10-point Likert scale from extremely to not at all)</p><p>In the past four weeks:</p><list list-type="bullet"><list-item><p>How much have your ITP symptoms or the effects of its treatments interfered with your ability to exercise?</p></list-item><list-item><p>To what extent has having ITP limited the types of physical or sporting activities you participate in?</p></list-item><list-item><p>Did you participate in sport? (yes/no)</p></list-item><list-item><p>Are you fearful of doing sport because of ITP? (yes/no)</p></list-item></list></sec></sec><sec><title>Emotional health</title><sec><title>Psychological scale</title><p>In the past four weeks:</p><list list-type="bullet"><list-item><p>How often did you feel like you have no control over your health because of your ITP or its treatments? ( 10-point Likert scale from all the time to never)</p></list-item><list-item><p>How often did you feel like you were unable to manage stress because of ITP or its treatments? (10-point Likert scale from all the time to never)</p></list-item><list-item><p>How often did you have feelings of sadness or depression because of ITP or its treatments? (10-point Likert scale from all the time to never)</p></list-item><list-item><p>Overall, how much has ITP or its treatments affected you psychologically (mental state, emotions)? (10-point Likert scale from extremely to not at all)</p></list-item><list-item><p>Overall, how bothered have you been by the effect that ITP or its treatments has had on you psychologically (mental state, emotions)? (10-point Likert scale from extremely to not at all)</p></list-item></list></sec><sec><title>Fear scale</title><p>(10-point Likert scale from extremely fearful to not at all fearful)</p><p>In the past four weeks:</p><list list-type="bullet"><list-item><p>How often have you been fearful of having a bleeding episode (eg, nose bleeds, gum bleeds)?</p></list-item><list-item><p>How fearful have you been of death or dying?</p></list-item><list-item><p>How fearful have you been of being too far away from your doctor in case you needed medical help?</p></list-item><list-item><p>How fearful have you been about getting an infection?</p></list-item><list-item><p>How fearful have you been of needing to have emergency surgery (due to concerns about bleeding during surgery)</p></list-item></list></sec><sec><title>Overall quality of life</title><p>In the past four weeks:</p><list list-type="bullet"><list-item><p>Overall, to what extent has ITP and its treatments affected your quality of life? (10-point Likert scale from extremely to not at all)</p></list-item><list-item><p>Overall, how bothered have you been by the effect of ITP and its treatments on your quality of life? (10-point Likert scale from extremely to not at all)</p></list-item><list-item><p>I have made significant changes to my lifestyle because I have ITP (10-point Likert scale from strongly agree to strongly disagree)</p></list-item><list-item><p>My ITP prevents me from doing things in life that I want to do (10-point Likert scale from strongly agree to strongly disagree)</p></list-item><list-item><p>My ITP prevents my spouse, partner, or family members from doing things in life that they want to do (10-point Likert scale from strongly agree to strongly disagree).</p></list-item></list></sec><sec><title>Social activity</title><p>In the past four weeks:</p><list list-type="bullet"><list-item><p>How often has having ITP limited your ability to participate in social activities? (10-point Likert scale from all the time to never)</p></list-item><list-item><p>How often have you avoided social activities to limit your exposure to infection? (10-point Likert scale from all the time to never)</p></list-item><list-item><p>How bothered were you by what people might think about your bruising or scarring? (10-point Likert scale from extremely to not at all)</p></list-item><list-item><p>To what extent have you been unable to lead a normal social life because of your ITP? (10-point Likert scale from extremely to not at all)</p></list-item></list></sec><sec><title>Women’s reproductive health (to be completed by women only)</title><p>Menstrual symptom subscale (10-point Likert scale from extremely to not at all)</p><p>Thinking about your last period:</p><list list-type="bullet"><list-item><p>How bothered were you by heavier bleeding than before having ITP?</p></list-item><list-item><p>How bothered were you by bleeding for more days than before having ITP?</p></list-item><list-item><p>How bothered were you by more pain than before having ITP?</p></list-item></list><p>Fertility subscale (10-point Likert scale from extremely to not at all)</p><list list-type="bullet"><list-item><p>How much has having ITP made it less likely that you would get pregnant?</p></list-item><list-item><p>How much has having ITP made it less likely that you would give birth?</p></list-item><list-item><p>How much has having ITP made it less likely that you would adopt?</p></list-item></list><p>Work (10-point Likert scale from extremely to not at all, with a not applicable option)</p><p>Since you were diagnosed:</p><list list-type="bullet"><list-item><p>To what degree has ITP negatively interfered with your choice of careers?</p></list-item><list-item><p>How much has ITP negatively interfered with your ability to get a promotion at your job?</p></list-item><list-item><p>How much has ITP negatively interfered with your relationship with coworkers?</p></list-item><list-item><p>How fearful have you been of losing your job because of your ITP?</p></list-item></list></sec><sec><title>Supplementary questions</title><p>Since your last ITP-PAQ:</p><list list-type="bullet"><list-item><p>How many platelet tests have you have had done on average? (six-point Likert scale from &lt;1 to &gt;4)</p></list-item><list-item><p>Have you travelled more than 200 km far away from your residence? (yes/no)</p></list-item><list-item><p>Are you fearful of travelling because of ITP? (yes/no)</p></list-item><list-item><p>Have you travelled abroad? (yes/no)</p></list-item><list-item><p>Are you fearful of travelling abroad because of ITP? (yes/no)</p></list-item></list></sec><sec><title>Your medical or paramedical consultations since your last questionnaire</title><p>Date</p><p>Type of caregiver</p><p>Consultation concerning ITP ?(yes/no)</p><p>Have you shown your Sanoia tool? (yes/no)</p><p>Has your Sanoia tool been useful to the consultation? (yes/no)</p><p>Comments</p><fig id="f3-ppa-6-725" position="anchor"><graphic xlink:href="ppa-6-725f3a"></graphic><graphic xlink:href="ppa-6-725f3b"></graphic><graphic xlink:href="ppa-6-725f3c"></graphic></fig></sec></sec></app></app-group><ref-list><title>References</title><ref id="b1-ppa-6-725"><label>1</label><element-citation publication-type="webpage"><source>Orphanet: the portal for rare diseases and orphan drugs</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.orpha.net">http://www.orpha.net</ext-link></comment><date-in-citation>Accessed September 10, 2010</date-in-citation></element-citation></ref><ref id="b2-ppa-6-725"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JN</given-names></name><name><surname>Woolf</surname><given-names>SH</given-names></name><name><surname>Raskob</surname><given-names>GE</given-names></name><etal></etal></person-group><article-title>Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology</article-title><source>Blood</source><year>1996</year><volume>88</volume><fpage>3</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">8704187</pub-id></element-citation></ref><ref id="b3-ppa-6-725"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathias</surname><given-names>SD</given-names></name><name><surname>Bussel</surname><given-names>JB</given-names></name><name><surname>George</surname><given-names>JN</given-names></name><name><surname>McMillan</surname><given-names>R</given-names></name><name><surname>Okano</surname><given-names>GJ</given-names></name><name><surname>Nichol</surname><given-names>JL</given-names></name></person-group><article-title>A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation</article-title><source>Health Qual Life Outcomes</source><year>2007</year><volume>5</volume><fpage>11</fpage><pub-id pub-id-type="pmid">17316442</pub-id></element-citation></ref><ref id="b4-ppa-6-725"><label>4</label><element-citation publication-type="webpage"><collab>Sanoia</collab><source>La fiche Santé anonyme</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.sanoia.com/fiche-sante/">http://www.sanoia.com/fiche-sante/</ext-link></comment><date-in-citation>Accessed May 3, 2012</date-in-citation></element-citation></ref><ref id="b5-ppa-6-725"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trijau</surname><given-names>S</given-names></name><name><surname>Servy</surname><given-names>H</given-names></name><name><surname>Selamnia</surname><given-names>A</given-names></name><name><surname>Pradel</surname><given-names>V</given-names></name><name><surname>Lafforgue</surname><given-names>P</given-names></name><name><surname>Pham</surname><given-names>T</given-names></name></person-group><article-title>Personal health records in rheumatoid arthritis: quality and adhesion factors</article-title><source>Arthritis Rheum</source><year>2011</year><volume>63</volume><fpage>S10</fpage></element-citation></ref><ref id="b6-ppa-6-725"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anhøj</surname><given-names>J</given-names></name><name><surname>Moldrup</surname><given-names>C</given-names></name></person-group><article-title>Feasibility of collecting diary data from asthma patients through mobile phones and SMS (short message service): response rate analysis and focus group evaluation from a pilot study</article-title><source>J Med Internet Res</source><year>2004</year><volume>6</volume><fpage>e42</fpage><pub-id pub-id-type="pmid">15631966</pub-id></element-citation></ref><ref id="b7-ppa-6-725"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JN</given-names></name><name><surname>Mathias</surname><given-names>SD</given-names></name><name><surname>Go</surname><given-names>RS</given-names></name><etal></etal></person-group><article-title>Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials</article-title><source>Br J Haematol</source><year>2009</year><volume>144</volume><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">19016720</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ppa-6-725" position="float"><label>Figure 1</label><caption><p>Sanoia interface. The Sanoia interface already includes various information corresponding to vaccination records, allergies, prescription history, and previous symptoms (<bold>A</bold>), and medical test results (<bold>B</bold>). Once the personal health record is created, the patient receives a personal unique identifier online that he/she can keep with them (<bold>C</bold>). This can be communicated to any health care provider, who can then access the medical information in four languages (<bold>D</bold>).</p></caption><graphic xlink:href="ppa-6-725f1"></graphic></fig><fig id="f2-ppa-6-725" position="float"><label>Figure 2</label><caption><p>Sanoia options in the customized interface for patients with ITP (the tool). The existing interface of Sanoia was expanded with ITP-specific tools, including addition of a link to ITP-related web resources validated by physicians (<bold>A</bold>), and a section for personal (bloc) notes for symptoms, medications, or intercurrent events (<bold>B</bold>).</p><p><bold>Abbreviation:</bold> ITP, immune thrombocytopenic purpura.</p></caption><graphic xlink:href="ppa-6-725f2"></graphic></fig><table-wrap id="t1-ppa-6-725" position="float"><label>Table 1</label><caption><p>Patient characteristics at enrolment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"></th><th align="left" valign="top" rowspan="1" colspan="1">Group 1 (n = 15)</th><th align="left" valign="top" rowspan="1" colspan="1">Groups 2 and 3 (n = 28)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="top" rowspan="1" colspan="1">44 (19–67)</td><td align="left" valign="top" rowspan="1" colspan="1">49 (21–73)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (female), %</td><td align="left" valign="top" rowspan="1" colspan="1">73.3</td><td align="left" valign="top" rowspan="1" colspan="1">75</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean duration of ITP, (years)</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Splenectomy, %</td><td align="left" valign="top" rowspan="1" colspan="1">33.3</td><td align="left" valign="top" rowspan="1" colspan="1">28.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic treatments,<xref ref-type="table-fn" rid="tfn2-ppa-6-725">*</xref> n</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Steroids</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TPO agonists</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other<xref ref-type="table-fn" rid="tfn3-ppa-6-725">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Platelets (Giga/L)</td><td align="left" valign="top" rowspan="1" colspan="1">120 (4–450)</td><td align="left" valign="top" rowspan="1" colspan="1">160 (16–453)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ppa-6-725"><p><bold>Notes:</bold> Unless otherwise specified, results are given as their medians (range).</p></fn><fn id="tfn2-ppa-6-725"><label>*</label><p>Intercurrent treatments (ie, short corticosteroid therapy initiated for a flareup of the disease) were not taken into account.</p></fn><fn id="tfn3-ppa-6-725"><label>**</label><p>disulone, hydroxychloroquine.</p></fn><fn id="tfn4-ppa-6-725"><p><bold>Abbreviations:</bold> ITP, immune thrombocytopenic purpura; TPO, thrombopoietin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ppa-6-725" position="float"><label>Table 2</label><caption><p>Usability of the study tool and impact on quality of life</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"></th><th align="left" valign="top" rowspan="1" colspan="1">Group 1 (n = 15)</th><th align="left" valign="top" rowspan="1" colspan="1">Group 2 (n = 14)</th><th align="left" valign="top" rowspan="1" colspan="1">Group 3 (n = 14)</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1">Usability of the tool</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Users<xref ref-type="table-fn" rid="tfn6-ppa-6-725">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">–</td><td align="left" valign="top" rowspan="1" colspan="1">19 (68%)</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Connections<xref ref-type="table-fn" rid="tfn7-ppa-6-725">#</xref></td><td align="left" valign="top" rowspan="1" colspan="1">–</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1–12)</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Personal notes<xref ref-type="table-fn" rid="tfn8-ppa-6-725">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">–</td><td align="left" valign="top" rowspan="1" colspan="1">15 (78%)</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Impact on QoL<xref ref-type="table-fn" rid="tfn9-ppa-6-725">##</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall QoL at baseline (M0)</td><td align="left" valign="top" rowspan="1" colspan="1">89 (27, 100)</td><td align="left" valign="top" rowspan="1" colspan="1">98 (36, 100)</td><td align="left" valign="top" rowspan="1" colspan="1">92 (16, 100)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Change in QoL, baseline to M1</td><td align="left" valign="top" rowspan="1" colspan="1">0 (−27, 16)</td><td align="left" valign="top" rowspan="1" colspan="1">−3 (−47, 24)</td><td align="left" valign="top" rowspan="1" colspan="1">−2 (−18, 27)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Change in QoL, baseline to M3</td><td align="left" valign="top" rowspan="1" colspan="1">0 (−27, 33)</td><td align="left" valign="top" rowspan="1" colspan="1">−20 (−42, 24)</td><td align="left" valign="top" rowspan="1" colspan="1">−2 (−18, 20)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Change overall QoL, baseline to M6</td><td align="left" valign="top" rowspan="1" colspan="1">−7 (−49, 7)</td><td align="left" valign="top" rowspan="1" colspan="1">−13 (−56, −1)</td><td align="left" valign="top" rowspan="1" colspan="1">−9 (−20, 2)</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-ppa-6-725"><p><bold>Notes:</bold></p></fn><fn id="tfn6-ppa-6-725"><label>*</label><p>At least one connection to the tool during the study period;</p></fn><fn id="tfn7-ppa-6-725"><label>#</label><p>Number of connections by users;</p></fn><fn id="tfn8-ppa-6-725"><label>**</label><p>at least one use of the “personal notes” section by users;</p></fn><fn id="tfn9-ppa-6-725"><label>##</label><p>QoL (quality of life) evaluated using the immune thrombocytopenic purpura patient assessment questionnaire (maximum score of 100).<sup>3</sup> Results are shown as the median and range.</p></fn></table-wrap-foot></table-wrap></floats-group></article>